Inclusion Criteria:

- Histologic and/or cytological proven breast cancer.

- Patients with metastases of breast cancer ± postmenopausal primary tumor ≥12 months.

- Positive oestrogen receptors (ER+), positive progesterone receptors (PgR+) or unknown
hormonal receptors (if duration between surgery and metastasis occurring is not less
2 years) which are indirect confirmation of hormone sensitive tumor.

- ECOG performance status of ≤ 2

- Patient willingness to take part in the programm

- Life expectancy of more than 6 months.

- Patient ability to complete a questionnaire.

Exclusion Criteria:

- Contraindications for Faslodex therapy

- Other anticancer therapy (chemotherapy, hormonal therapy with other drugs,
radiotherapy), except for radiotherapy of sites which are not only measurable or
evaluable manifestation of disease.